Equities researchers at StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a note issued to investors on Wednesday. The firm set a “sell” rating on the stock.
Separately, Roth Mkm reiterated a “buy” rating and set a $20.00 target price on shares of Bio-Path in a report on Monday, July 8th.
Get Our Latest Analysis on Bio-Path
Bio-Path Trading Up 4.7 %
Bio-Path (NASDAQ:BPTH – Get Free Report) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.54) by $0.38. During the same quarter in the previous year, the company earned ($10.60) earnings per share. On average, analysts predict that Bio-Path will post -6.2 earnings per share for the current year.
Institutional Trading of Bio-Path
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is currently owned by hedge funds and other institutional investors.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also
- Five stocks we like better than Bio-Path
- What Are Trending Stocks? Trending Stocks Explained
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- About the Markup Calculator
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.